These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31538325)

  • 1. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
    Ogasawara R; Hashimoto D; Sugita J; Yamawaki F; Naka T; Mitsuhashi T; Takahashi S; Miyashita N; Okada K; Onozawa M; Matsuno Y; Teshima T
    Int J Hematol; 2020 Mar; 111(3):475-479. PubMed ID: 31538325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Resistant GvHD in a Patient Treated with Nivolumab for Hodgkins Lymphoma Relapse after Allogeneic Unrelated Transplantation.
    Steinerová K; Jindra P; Lysák D; Karas M
    Klin Onkol; 2019; 32(1):66-69. PubMed ID: 30764632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of CD8 + T cells expressing nivolumab-free PD-1 with clinical status in a patient with relapsed refractory classical Hodgkin lymphoma.
    Kowata S; Seki Y; Tsukushi Y; Sato T; Asano K; Maeta T; Yashima-Abo A; Sasaki R; Okano Y; Oyake T; Ito S
    Int J Hematol; 2023 Dec; 118(6):751-757. PubMed ID: 37488284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
    Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nivolumab in the Treatment of Hodgkin Lymphoma.
    Ansell SM
    Clin Cancer Res; 2017 Apr; 23(7):1623-1626. PubMed ID: 27881581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
    de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
    Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. γδ T cell clonal proliferation early after PD-1 blockade.
    Ono K; Onishi Y; Kobayashi M; Hatta S; Nasu K; Watanabe S; Ichikawa S; Okitsu Y; Fukuhara N; Harigae H
    Ann Hematol; 2019 Jan; 98(1):219-220. PubMed ID: 29946908
    [No Abstract]   [Full Text] [Related]  

  • 10. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.
    Minson A; Douglas G; Bilmon I; Grigg A
    Br J Haematol; 2019 Mar; 184(5):840-844. PubMed ID: 29532918
    [No Abstract]   [Full Text] [Related]  

  • 12. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
    Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
    Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Yared JA; Hardy N; Singh Z; Hajj S; Badros AZ; Kocoglu M; Yanovich S; Sausville EA; Ujjani C; Ruehle K; Goecke C; Landau M; Rapoport AP
    Bone Marrow Transplant; 2016 Jun; 51(6):850-2. PubMed ID: 26828905
    [No Abstract]   [Full Text] [Related]  

  • 14. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
    Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
    J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience.
    Dada R; Zabani Y
    J Oncol Pharm Pract; 2019 Oct; 25(7):1586-1589. PubMed ID: 30253728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.
    Wight JC; Hawkes EA; Berlangieri SU; Khor R; Grigg AP
    Leuk Lymphoma; 2018 Nov; 59(11):2749-2751. PubMed ID: 29569979
    [No Abstract]   [Full Text] [Related]  

  • 17. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis.
    Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J
    Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
    Dada R; Zekri J
    J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolerance and effectiveness of nivolumab after pediatric T-cell replete, haploidentical, bone marrow transplantation: A case report.
    Shad AT; Huo JS; Darcy C; Abu-Ghosh A; Esposito G; Holuba MJ; Robey N; Cooke KR; Symons HJ; Chen AR; Llosa NJ
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.